Cart
sales@molnova.com
CMX-521
CAS No. 2077178-99-3
CMX-521( —— )
Catalog No. M36317 CAS No. 2077178-99-3
CMX-521 has antiviral activity, inhibits oronavirus activity, and can be used in the study of viral infections.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 603 | Get Quote |
|
| 5MG | 922 | Get Quote |
|
| 10MG | 1121 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCMX-521
-
NoteResearch use only, not for human use.
-
Brief DescriptionCMX-521 has antiviral activity, inhibits oronavirus activity, and can be used in the study of viral infections.
-
DescriptionCMX-521 has antiviral activity, inhibits oronavirus activity, and can be used in the study of viral infections.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetAntiviral
-
RecptorAntiviral
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2077178-99-3
-
Formula Weight323.3
-
Molecular FormulaC13H17N5O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N)(=O)C=1C=2C(N(C1)[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)=NC(C)=NC2N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Tyrosine kinase-IN-7
Tyrosine kinase-IN-7 is a potent inhibitor of the tyrosine kinase EGFR, inhibiting EGFR(WT) and EGFR(T790M) and showing anti-cancer and anti-tumor activity in a variety of cancer cell lines.
-
(R,1R)-Tenofovir ami...
(R,1R)-Tenofovir amibufenamide ((R,1R)-HS-10234) is an orally administered Tenofovir prodrug with antiviral activity. Tenofovir is a nucleotide reverse transcriptase inhibitor.
-
cis-Vaccenic acid
cis-Vaccenic acid (Asclepic acid) is the antiviral extract from Rhodopseudomonas capsulate and the predominant active component of Rhodopseudomonas capsulate. cis-Vaccenic acid acts a potential fetal hemoglobin inducer.
